New hope for stomach cancer patients when immunotherapy fails
NCT ID NCT07392346
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of drugs for people with advanced stomach cancer that got worse after initial immunotherapy. The treatment includes a targeted therapy (fruquintinib), chemotherapy (nab-paclitaxel), and a new immunotherapy (iparomlimab and tuvonralimab). The goal is to see if this combination can shrink tumors and help patients live longer without their cancer growing. About 68 adults will take part in this single-arm phase 2 trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese PLA General Hospital, Beijing
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Acupuncture with a jolt: could needles shield nerves from chemo?
- Prehab before cancer surgery: could exercise and nutrition cut complications?
- New radiation 'Smart Bomb' targets Hard-to-Treat cancers in early trial
- New drug combo aims to tackle Hard-to-Treat HER2 cancers
- Real-World check: does adding nivolumab to chemo help stomach cancer patients?
- Fasting during immunotherapy: a new way to boost treatment?